Acute Coronary Syndrome Market
- The global acute coronary syndrome market was worth USD 20.4 billion in 2018 and is forecasted to reach USD 49.2 billion by 2026, at a CAGR of 11.70% during the forecast period.
- Acute coronary syndrome (ACS) refers to a spectrum of clinical presentations ranging from ST-segment elevation myocardial infarction (STEMI) to presentations found in non–ST-segment elevation myocardial infarction (NSTEMI) or in unstable angina.
- It is associated with rupture of an atherosclerotic plaque and partial or complete thrombosis of the infarct-related artery.
- Acute coronary syndrome (ASC) occurs when a blood clot suddenly forms within a coronary artery, usually due to the acute rupture of an atherosclerotic plaque.
- The blood clot may produce partial or complete blockage of the artery, either way placing the heart muscle supplied by that artery in immediate jeopardy.
Acute Coronary Syndrome Market Dynamics
- The increasing cases of hypertension are one of the factors fueling the global acute coronary syndrome market.
- High blood pressure is the main risk factor for stroke and risk factor for heart attack, heart failure, and kidney disease. There is also increasing evidence that it is a risk factor for vascular dementia.
- For instance, according to the Center for Disease Control and Prevention (CDC), around 75 million American adults with 32% have high blood pressure in 2016. 1 in 3 American adults has prehypertension.
- According to the National Heart Foundation of Australia, in 2015, 6 million Australians aged 18 years and over had high blood pressure.
- In 2015, the prevalence of uncontrolled or unmanaged high blood pressure was 20.4% in Western Australia and 25.2% in Tasmania.
- According to the Blood Pressure Association, around 16 million people in the UK have high blood pressure, of which 30% of women and 32% of men have high blood pressure in 2016.
- In 2016, around 62,000 death cases from stroke and heart attacks occurred due to poor blood pressure control.
- The risk for AFib increases with age. High blood pressure, which also increases in danger with advancing age, accounts for 14% to 22% of AFib cases.
- More than 750,000 hospitalizations occur each year because of AFib. The condition contributes to an estimated 130,000 deaths each year.
Acute Coronary Syndrome Market Segmentation Analysis
- Based on the type the global market for the acute coronary syndrome is broadly segmented as by ST-elevation myocardial infarction, non-ST elevation myocardial infarction, and unstable angina.
- Currently, ST-elevation myocardial infarction is showing significant growth, and it accounts for approximately XX% of the market, due to the regulatory approval for ST-elevation myocardial infarction drugs.
- For instance, in January 2018, Wacker Biotech GmbH, has received US Food and Drug Administration (FDA) approval to manufacture the drug substance in Retavase, a thrombolysis medication. The medication is used to treat acute myocardial infarction in adults. The drug Retavase used to treat acute ST-elevation myocardial infarction (STEMI).
- In March 2016 AstraZeneca received US Food and Drug Administration (FDA) approval for a new administration option for acute coronary syndrome (ACS) patients. BRILINTA is indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with ACS ST-elevation myocardial infarction [STEMI]. BRILINTA to be crushed and administered in water by swallowing or via nasogastric tube.
Acute Coronary Syndrome Market Geographical Analysis
- The global Acute Coronary Syndrome market is segmented into North America, Europe, Asia Pacific, South America, and ROW.
- North America is dominating the global Acute Coronary Syndrome market, the rising prevalence of hypertension, which is driving the market.
- For instance, according to the American Heart Association, in 2017, an estimated 103 million U.S. adults have high blood pressure.
- According to American Heart Association, the death rate from high blood pressure increased by nearly 11% in the United States between 2005 and 2015, and the actual number of deaths rose by almost 38%, which is up to almost 79,000 by 2015.
Acute Coronary Syndrome Market Competitive Trends
- The strategic alliance between companies and regulatory approval for acute coronary syndrome is one of the key factor driving the global Acute Coronary Syndrome market.
- For instance, in November 2018, AstraZeneca has received the US Food and Drug Administration (FDA) approval for the first generic medication indicated for lowering the risk of heart attack, or death from heart attack or stroke in patients with the acute coronary syndrome (ACS).
- Ticagrelor tablets, a generic version of Brilinta have been granted Abbreviated New Drug Application (ANDA) approval in 60 mg and 90 mg doses.
- In June 2015, Roche entered into an agreement with DalCor to develop a companion diagnostic (CDx) test for dalcetrapib, which will target patients with a specific genotype experiencing acute coronary syndrome (ACS).
- In June 2015, Sun Pharmaceutical Industries signed an agreement with AstraZeneca Pharma to distribute cardiology drug Axcer in India. Axcer is an additional brand of Astra drug ticagrelor that is used in treating acute coronary syndrome (ACS).
Why Purchase the Report?
• Visualize the composition of the acute coronary syndrome market across each indication, in terms of material type, and by drugs highlighting the key commercial assets and players.
• Identify business opportunities in critical coronary syndrome market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of the acute coronary syndrome market – level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the principal products of all major market players
• Equipment Suppliers/ Buyers
• Service Providers/ Buyers
• Industry Investors/Investment Bankers
• Education & Research Institutes
• Research Professionals
• Emerging Companies
Global Acute Coronary Syndrome Market
1. Acute Coronary Syndrome Market Scope and Methodology
1.1. Research Methodology
1.2. The scope of the market
2. Acute Coronary Syndrome Market Industry Trends
2.1. Key Market Trends and Developments in Acute Coronary Syndrome Market
3. Acute Coronary Syndrome Market Market Outlook
3.4. Pricing Analysis
3.6. Supply Chain Analysis
3.7. Reimbursement policies
3.8. Technological Advancements
3.9. PEST analysis
3.10. Porter’s Five Forces Analysis
4. Acute Coronary Syndrome Market Segmentation Analysis
4.1. By Type
4.1.1. ST-elevation Myocardial Infarction (STEMI)
4.1.2. Non-ST-Elevation Myocardial Infarction (NSTEMI)
4.1.3. Unstable Angina (UA)
4.2. By Drugs
4.2.3. Statin Drugs
5. Acute Coronary Syndrome Market Regional, Country-level Analysis
5.1. Geographic Overview
5.2. North America
5.2.1. The U.S.
5.3.2. The U.K.
5.3.6. Rest of Europe
5.4. South America
5.4.3. Rest of South America
5.5. Asia Pacific
5.5.5. Rest of Asia Pacific
5.6. Rest of World
6. Acute Coronary Syndrome Market Competitive Analysis
6.1. Competitive Scenario
6.2. Heat Map Analysis
6.3. Product Benchmarking
7. Acute Coronary Syndrome Market Company Profiles
7.1. Teva Pharmaceuticals
7.2. Dr. Reddy’s Laboratories
7.3. Boehringer Ingelheim
7.4. Johnson & Johnson
7.7. Amgen Inc.
7.8. AbbVie Inc.
7.9. AstraZeneca PLC
7.10. GlaxoSmithKline Plc
8. Acute Coronary Syndrome Market Key companies to watch
9. Acute Coronary Syndrome Market Emerging Companies
10. Acute Coronary Syndrome Market Appendix
10.2. List of Tables
10.3. Expert Panel Validation
10.5. Contact Us